Recipharm Expands US Sterile Fill and Finish Capabilities
Recipharm, a global contract development and manufacturing organization (CDMO), announced a multi-million-dollar investment in its US operations, strengthening its ability to support pharmaceutical and biotechnology companies with advanced sterile fill and finish services for biologics and advanced therapies.
The investment reflects Recipharm’s commitment to expanding US manufacturing capacity, accelerating development timelines and providing customers with seamless access to clinical and commercial manufacturing services.
The announcement follows the signing of a clinical biologics fill and finish agreement with a major global pharmaceutical company. Recipharm has also enhanced its aseptic manufacturing platform to support clinical and commercial programs for customers in North America and Europe, providing greater operational flexibility, rapid technology transfer and accelerated development pathways for complex sterile products.
Greg Behar, CEO of Recipharm, said: “The demand for biologics and advanced therapies continues to accelerate, and manufacturers must be ready to meet that challenge with the right capacity, expertise and technology. By expanding our sterile manufacturing capabilities, we are investing in the infrastructure needed to support the next wave of pharmaceutical innovation. This investment enables us to support more programs from development through commercial supply, while strengthening our ability to help customers scale efficiently and accelerate timelines.”
